Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)Michał Marzec, Mariusz A. Wasik, Qian Zhang et al.|Proceedings of the National Academy of Sciences|2008Cited by 723
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.Bruce Ruggeri, Craig A. Dionne, Candy Robinson et al.|PubMed|2003Cited by 124
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicitySheila Miknyoczki, Bruce Ruggeri, Hong Chang et al.|Molecular Cancer Therapeutics|2007Cited by 112
Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cellsWeihua Wan, Mangeng Cheng, Mark S. Albom et al.|Blood|2005Cited by 105
A New Class of Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Structure−Activity Relationships for a Series of 9-Alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazole-5-ones and the Identification of CEP-5214 and Its Dimethylglycine Ester Prodrug Clinical Candidate CEP-7055Diane E. Gingrich, Robert L. Hudkins, D. Rajagopala Reddy et al.|Journal of Medicinal Chemistry|2003Cited by 74